Top Stories
Cloud breach exposed proprietary information as the drugmaker launches an investigation.
The multi-year study will test whether OhmX can give labs a clearer view of structural variants in AML and MDS without having to piece together results from multiple tests.
The company's plan to bring provider-led GLP-1 prescribing and digital chronic care together is the first commercial offering to emerge from its partnership with Beluga Health.
The funding comes less than a year after the startup raised nearly $300 million in a series B round that valued Function at $2.5 billion.
Expanded partnership focuses on generating large-scale cellular datasets to train foundation models and uncover novel therapeutic targets.
Conference News
Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...
Second Quarter Revenue Growth of 52% to $132 MillionRaises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionBRISBANE, Calif.--(BUSINE...
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and ScreeningRaises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Cali...
Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025Raising full-year 2026 revenue guidan...
Revenue of $85.4 million, growing 20.1% sequentiallyGAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3%GAAP los...
